Methods for treating neurodegenerative disorders
Inventors
Kocis, Petr • TOLAR, Martin • Hey, John
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11077095-B2
Publication Date
2021-08-03
Expiration Date
Abstract
Methods of treating a disease characterized by amyloid aggregates are provided herein.
Core Innovation
The invention relates to methods and pharmaceutical uses for treating Alzheimer’s disease and amyloid-aggregate diseases characterized by amyloid and amyloid-like aggregates. The approach administers compounds selected from the depicted compound set or pharmaceutically acceptable salts, with the compound set presented as the defined chemical matter for the therapeutic method.
The disclosure describes compounds featuring sulfonic acid and sulfonate groups, amino-containing heteroaromatic ring systems, and fused ring systems with additional variations in ring systems and amino substituents. It also references tautomeric, stereoisomeric, and prodrug-related definitions tied to the compound sets and includes pharmaceutically acceptable carriers and pharmaceutically acceptable compositions.
The background context addresses amyloid plaques, neurofibrillary tangles, and soluble oligomeric Aβ/beta-amyloid oligomers, and prior approaches including tramiprosate/SAPS and its prodrug ALZ-801. The document emphasizes a need for additional agents that can act as amyloid anti-aggregation, disaggregation, or prevention agents.
Claims Coverage
The independent claim family covers 1 method of treating Alzheimer’s disease by administering to a subject in need thereof a compound selected from the depicted compound set or a pharmaceutically acceptable salt. Dependent coverage adds a pharmaceutically acceptable composition with a pharmaceutically acceptable carrier, for a total of two inventive features.
Treating alzheimer’s disease by administering a selected compound or a pharmaceutically acceptable salt
A method of treating Alzheimer’s disease comprising administering to a subject in need thereof a compound selected from the compounds described in the patent, or a pharmaceutically acceptable salt of any of the foregoing.
Formulating the compound into a pharmaceutically acceptable composition with a pharmaceutically acceptable carrier
The method further includes formulating the compound into a pharmaceutically acceptable composition including a pharmaceutically acceptable carrier.
Overall, the claim coverage centers on treating Alzheimer’s disease by administration of a compound selected from the depicted structural formula compound set or pharmaceutically acceptable salts, with dependent refinement for formulation in a pharmaceutically acceptable composition containing a pharmaceutically acceptable carrier.
Stated Advantages
The document emphasizes a need for additional agents that can act as amyloid anti-aggregation, disaggregation, or prevention agents.
Documented Applications
Treating Alzheimer’s disease by administering the selected compound or a pharmaceutically acceptable salt to a subject in need thereof.
Interested in licensing this patent?